Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
August 8, 2016 4:31 PM EDTPatient Screening Underway for Fabry Phase III Clinical Trial
Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End
CARMIEL, Israel, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), today announced financial results for the fiscal quarter ended June 30, 2016.
We remain focused on developing our clinical assets, and now have three drugs being evaluated in clinical trials, said Moshe Manor, Protalixs President and Chief Executive Officer. Â We are currently screening patients in our phase... More
